KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) Return on Equity: 2011-2025

Historic Return on Equity for Acadia Pharmaceuticals (ACAD) over the last 14 years, with Sep 2025 value amounting to 0.30%.

  • Acadia Pharmaceuticals' Return on Equity rose 7.00% to 0.30% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.30%, marking a year-over-year increase of 7.00%. This contributed to the annual value of 0.39% for FY2024, which is 54.00% up from last year.
  • Per Acadia Pharmaceuticals' latest filing, its Return on Equity stood at 0.30% for Q3 2025, which was up 7.29% from 0.28% recorded in Q2 2025.
  • Over the past 5 years, Acadia Pharmaceuticals' Return on Equity peaked at 0.35% during Q4 2024, and registered a low of -0.52% during Q4 2022.
  • Moreover, its 3-year median value for Return on Equity was 0.06% (2024), whereas its average is 0.03%.
  • As far as peak fluctuations go, Acadia Pharmaceuticals' Return on Equity decreased by 22bps in 2022, and later skyrocketed by 63bps in 2024.
  • Over the past 5 years, Acadia Pharmaceuticals' Return on Equity (Quarterly) stood at -0.30% in 2021, then fell by 22bps to -0.52% in 2022, then skyrocketed by 37bps to -0.15% in 2023, then spiked by 50bps to 0.35% in 2024, then grew by 7bps to 0.30% in 2025.
  • Its Return on Equity stands at 0.30% for Q3 2025, versus 0.28% for Q2 2025 and 0.31% for Q1 2025.